Detection of cardiac fibrosis by LGE MRI and circulating biomarkers in patients with myocardial infarction.
Completed
- Conditions
- myocardial infarction10028593
- Registration Number
- NL-OMON44735
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 78
Inclusion Criteria
Subject is diagnosed with acute myocardial infarction.
Subject is 18 years or older.
Exclusion Criteria
Subject with known prior acute myocardial infarction, cardiac surgery, or valvular diseases.
Subject is implanted with MRI incompatible prostheses or devices.
Subject has an indication for implantable cardio defibrillator.
Subject is in a condition that alters the collagen turnover.
Subject underwent recent trauma or surgery in the last 6 months.
Subject is diagnosed with kidney failure.
Subject is known with an allergy against gadolinium-based contrast agents.
Subject is familiar with claustrophobia.
Subject is pregnant or has given birth within the past 90 days.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- Cardiac fibrosis determined by contrast MRI at 4-6 months after myocardial<br /><br>infarction.<br /><br>- Circulating biomarkers (related to fibrosis) at 4-6 months after myocardial<br /><br>infarction.</p><br>
- Secondary Outcome Measures
Name Time Method <p>- Circulating biomarkers (related to fibrosis) at other time points.<br /><br>- New circulating biomarkers (related to fibrosis and cardiac function)<br /><br>- Cardiac function<br /><br>- Death<br /><br>- Composite endpoint of non-fatal myocardial infarction, stroke, cardiovascular<br /><br>hospitalisation or cardiovascular death.<br /><br>- Heart failure<br /><br>- Fibrosis determined with new MRI techniques</p><br>